The pill imprinted with H126 is Pantoprazole Sodium Delayed-Release 40 mg, distributed primarily by Camber Pharmaceuticals. It is a prescription medication belonging to the proton pump inhibitor (PPI) drug class and is used to reduce stomach acid production.
Pill Identification
Property – Details
- Imprint –
H126(printed in black ink on one side) - Color & Shape – Yellow to pale yellow, oval, biconvex tablet
- Size – 12 mm
- Active Ingredient – Pantoprazole Sodium 40 mg (equivalent to 40 mg pantoprazole base)
- Drug Class – Proton Pump Inhibitor (PPI)
- Controlled Substance – No (Not a controlled drug)
- Labeler / Supplier – Camber Pharmaceuticals, Inc.
Mechanism of Action
Pantoprazole works by inhibiting gastric acid secretion at the final enzymatic step:
- Targeting the Proton Pump: Pantoprazole is a substituted benzimidazole that accumulates in the acidic environment of the parietal cells in the stomach.
- Enzyme Inhibition: It binds covalently to the ATPase enzyme system (commonly referred to as the “proton pump”) on the secretory surface of gastric parietal cells.
- Acid Reduction: By inhibiting this enzyme, pantoprazole suppresses both basal and stimulated gastric acid production, regardless of the stimulus (acetylcholine, histamine, or gastrin).
Because it is formulated as a delayed-release tablet, the active drug is protected from premature degradation by stomach acid and dissolves in the higher pH environment of the duodenum.
Indications and Clinical Usage
Pantoprazole 40 mg delayed-release tablets are FDA-approved for:
- Short-Term Treatment of Erosive Esophagitis: Healing and symptom relief of erosive esophagitis associated with Gastroesophageal Reflux Disease (GERD).
- Maintenance of Healing of Erosive Esophagitis: Reducing relapse rates of daytime and nighttime heartburn.
- Pathological Hypersecretory Conditions: Long-term treatment of conditions involving excessive acid production, such as Zollinger-Ellison (ZE) Syndrome.
Dosing and Administration
- Erosive Esophagitis (GERD): The typical adult dose is 40 mg once daily for up to 8 weeks. An additional 8-week course may be considered for patients who have not fully healed.
- Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison): The standard starting adult dose is 40 mg twice daily, adjusted based on patient need up to 240 mg per day.
- Administration Rules: * Swallow the tablet whole with or without food.
- Do NOT crush, split, or chew the tablet, as breaking the enteric coating destroys its delayed-release functionality.
Side Effects
Common Adverse Effects
- Gastrointestinal: Diarrhea, nausea, abdominal pain, flatulence, and vomiting.
- Neurological: Headache and dizziness.
- General: Joint pain (arthralgia).
Serious Adverse Effects
- Clostridioides difficile-Associated Diarrhea: Severe, watery diarrhea that does not stop.
- Bone Fractures: Long-term or high-dose PPI use increases the risk of osteoporosis-related fractures of the hip, wrist, or spine.
- Cutaneous or Systemic Lupus Erythematosus: New or worsening autoimmune symptoms (e.g., joint pain, skin rash on cheeks/arms).
- Severe Hypomagnesemia: Low blood magnesium levels following prolonged use (typically over 1 year), which can cause muscle spasms, tremors, or cardiac arrhythmias.
- Acute Interstitial Nephritis: An allergic kidney reaction that can occur at any point during treatment.
Precautions and Drug Interactions
Key Contraindications
- Hypersensitivity: Contraindicated in patients with known hypersensitivity to pantoprazole, substituted benzimidazoles, or any inactive component of the formulation.
- Co-administration with Rilpivirine: Contraindicated with HIV medications containing rilpivirine because reduced stomach acidity significantly decreases rilpivirine absorption and efficacy.
Important Drug Interactions
- pH-Dependent Absorption Drugs: Lower stomach acid reduces the absorption of drugs like antiretrovirals (e.g., atazanavir), ketoconazole, itraconazole, and iron salts.
- Methotrexate: Concomitant use with high-dose methotrexate may elevate and prolong serum levels of methotrexate, increasing toxicity risks.
- Warfarin: May increase International Normalized Ratio (INR) and prothrombin time, increasing the risk of abnormal bleeding.
Long-Term Monitoring
- Vitamin B12 Deficiency: Long-term acid suppression (greater than 3 years) can impair the absorption of dietary vitamin B12.
- Bone Density: Patients on prolonged therapy should be monitored for bone health and may require calcium and vitamin D supplementation.